Precision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification

Childhood obesity is a heterogeneous chronic disease shaped by genetic susceptibility, neuroendocrine signaling, energy homeostasis, adipose dysfunction, insulin resistance, and environmental exposure. Glucagon-like peptide-1 (GLP-1) receptor agonists have markedly improved treatment efficacy, but heterogeneous response, weight recurrence after withdrawal, residual organ risk, and limited long-term pediatric data expose the limitations of a single-pathway, weight-centered model. This narrative review integrates the molecular rationale and clinical evidence for precision pharmacotherapy beyond single GLP-1 receptor agonism. It examines glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and GLP-1/glucagon co-agonism, triple agonism, amylin combinations, fibroblast growth factor 21 (FGF21) analogues, leptin replacement, and melanocortin-4 receptor (MC4R) agonism, separating established pediatric evidence from adult proof-of-concept and preclinical inference. Genotype-directed treatment for monogenic and syndromic obesity and lesion-directed treatment for acquired hypothalamic obesity provide the clearest examples of causal pathway correction. For common obesity, treatment selection should integrate developmental stage, hyperphagia, insulin resistance, ectopic fat, body composition, genetic context, treatment burden, and early response. Disease modification should be evaluated across growth, puberty, bone and lean tissue, beta cell and hepatic health, physical function, psychosocial well-being, safety, and durability. A dynamic cycle of phenotyping, mechanism-based treatment, multidomain monitoring, adaptation, and longitudinal re-phenotyping may improve the clinical relevance of pediatric obesity care.